DE69032599D1 - Gegengifte und verfahren zu deren herstellung - Google Patents

Gegengifte und verfahren zu deren herstellung

Info

Publication number
DE69032599D1
DE69032599D1 DE69032599T DE69032599T DE69032599D1 DE 69032599 D1 DE69032599 D1 DE 69032599D1 DE 69032599 T DE69032599 T DE 69032599T DE 69032599 T DE69032599 T DE 69032599T DE 69032599 D1 DE69032599 D1 DE 69032599D1
Authority
DE
Germany
Prior art keywords
venoms
whole
antivenom
atrox
durissus terrificus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69032599T
Other languages
English (en)
Inventor
Sean B Carroll
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23704763&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69032599(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69032599D1 publication Critical patent/DE69032599D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/804—Drug, bio-affecting and body treating compositions involving IgG3, IgG4, IgA, or IgY
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/824—Immunological separation techniques
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813—Carrier is a saccharide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855—Proteins from animals other than mammals or birds
    • Y10S530/856—Snakes; venom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855—Proteins from animals other than mammals or birds
    • Y10S530/858—Proteins from animals other than mammals or birds insects; venom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/861—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgG3, IgG4, IgA, or IgY
DE69032599T 1989-10-31 1990-10-31 Gegengifte und verfahren zu deren herstellung Expired - Lifetime DE69032599D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/429,791 US5196193A (en) 1989-10-31 1989-10-31 Antivenoms and methods for making antivenoms
PCT/US1990/006341 WO1991006306A1 (en) 1989-10-31 1990-10-31 Antivenoms and methods for making antivenoms

Publications (1)

Publication Number Publication Date
DE69032599D1 true DE69032599D1 (de) 1998-10-01

Family

ID=23704763

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69032599T Expired - Lifetime DE69032599D1 (de) 1989-10-31 1990-10-31 Gegengifte und verfahren zu deren herstellung

Country Status (5)

Country Link
US (4) US5196193A (de)
EP (1) EP0498854B1 (de)
AT (1) ATE170079T1 (de)
DE (1) DE69032599D1 (de)
WO (1) WO1991006306A1 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736139A (en) 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5196193A (en) * 1989-10-31 1993-03-23 Ophidian Pharmaceuticals, Inc. Antivenoms and methods for making antivenoms
US5599539A (en) * 1989-10-31 1997-02-04 Ophidian Pharmaceuticals, Inc. Therapy for clostridial botulinum toxin
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
WO1996012802A1 (en) * 1989-10-31 1996-05-02 Ophidian Pharmaceuticals, Inc. Vaccine and antitoxin for treatment and prevention of c. difficile disease
US5719267A (en) * 1989-10-31 1998-02-17 Ophidian Pharmaceuticals Inc. Clostridial toxin disease therapy
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5342830A (en) * 1990-11-16 1994-08-30 Cor Therapeutics, Inc. Antithrombosis agents
GB9109478D0 (en) * 1991-05-02 1991-06-26 Therapeutic Antibodies Inc Antivenoms
US5605691A (en) * 1992-09-17 1997-02-25 Ophidian Pharmaceuticals, Inc. Immunologically active proteins from inclusion bodies
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
US7037680B2 (en) 1993-09-21 2006-05-02 The United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7227010B2 (en) * 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
DE69511860T2 (de) * 1994-05-31 2000-02-10 Allergan Inc Modifizierung von clostridium-toxinen und ihre anwendung als transport proteine
GB9410871D0 (en) 1994-05-31 1994-07-20 Imperial College Modification of tetanus toxin for use as a transport protein
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US5849110A (en) * 1996-11-04 1998-12-15 The Boeing Company Sol coating of metals
US5869141A (en) * 1996-11-04 1999-02-09 The Boeing Company Surface pretreatment for sol coating of metals
US6037060A (en) * 1996-11-04 2000-03-14 The Boeing Company Sol for bonding expoxies to aluminum or titanium alloys
US5814137A (en) * 1996-11-04 1998-09-29 The Boeing Company Sol for coating metals
US5958578A (en) * 1996-11-04 1999-09-28 The Boeing Company Hybrid laminate having improved metal-to-resin adhesion
IL123001A (en) * 1998-01-20 1998-12-06 Shulov Inst For Venom Research Analgesic fraction from snake March and pharmacy preparations containing it
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7241443B1 (en) 1999-07-15 2007-07-10 Camas Incorporated Immunogen adherence inhibitor and method of making and using same
US7238351B2 (en) * 1999-07-15 2007-07-03 Peter Nash Immunogen adherence inhibitor directed to lactic acid producing organisms and method of making and using it
US6673346B1 (en) * 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
US20080038274A1 (en) * 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
DE19961141A1 (de) * 1999-12-17 2001-07-26 Mack Gerd R Pharmazeutische Zusammensetzung aus Spinnengiften sowie deren Herstellung und Verwendung zur Behandlung von Tumorerkrankungen
DE10024383B4 (de) * 2000-05-17 2005-07-21 Mack, Gerd R. Mit toxischen Substanzen beladene dendritische Zellen
US6608172B1 (en) 2000-06-09 2003-08-19 Good Biotech Corporation Isolation of IgY (ΔFc) antibodies
US6680376B2 (en) * 2000-12-08 2004-01-20 Good Biotech Corporation Process for selectively isolating avian immunoglobulins
US8173783B2 (en) * 2000-12-08 2012-05-08 Good Biotech Corporation Process for selectively isolating IgY antibodies from egg yolk of an anseriform bird and IgY antibodies obtained thereby
US6709655B2 (en) * 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
US20030211330A1 (en) * 2002-05-09 2003-11-13 Anderson Robert A. Method of preparing a metal material for bonding
US20040076630A1 (en) * 2002-09-18 2004-04-22 Maurine Pearson Method for creating antigens using Emus
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
PT2316852E (pt) * 2002-11-08 2014-06-23 Ablynx Nv Anticorpos de domínio único estáveis
NZ563471A (en) * 2002-11-08 2009-04-30 Ablynx Nv Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
US7335759B2 (en) * 2002-12-02 2008-02-26 Universidad Nacional Autónoma de Méxica (UNAM) Recombinant immunogens for the generation of antivenoms to the venom of scorpions of the genus Centruroides
US9701737B2 (en) * 2003-02-19 2017-07-11 Camas, Incorporated Immunogen adherence and method of making and using same
MXPA03003959A (es) * 2003-03-18 2004-09-23 Invest Aplic S A De C V Uso de inmunoglobulinas procedentes de yema de huevo, para el tratamiento de infecciones causados por parasitos, tanto en animales como en el humano.
KR101424624B1 (ko) * 2003-05-14 2014-07-31 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
US20060210563A1 (en) * 2003-07-25 2006-09-21 Juan Lopez De Silanes Administration of anti-cytokine f(ab')2 antibody fragments
US20070258986A1 (en) * 2003-11-19 2007-11-08 Govt of the US as represented by the secretary, Targeted Delivery System for Bioactive Agents
AU2003290419A1 (en) * 2003-12-31 2005-07-21 Council Of Scientific And Industrial Research A process for preparing egg yolk antibodies
US8491914B2 (en) 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
US8551480B2 (en) * 2004-02-13 2013-10-08 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US9481878B2 (en) 2004-02-13 2016-11-01 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
WO2006130161A2 (en) * 2004-07-21 2006-12-07 The Cornell Research Foundation, Inc. Therapeutic compounds derived from spider venom and their method of use
MXPA04008435A (es) 2004-08-31 2006-03-02 Univ Mexico Nacional Autonoma Inmunogeno y anti-veneno contra el veneno de la arana violinista.
DE102004055891B4 (de) * 2004-11-19 2007-08-30 Wiesner, Henning, Prof., Dr. Gemische von Schlangengiften zur Krankheitsbekämpfung
US9623115B2 (en) * 2005-04-06 2017-04-18 Ibc Pharmaceuticals, Inc. Dock-and-Lock (DNL) Complexes for Disease Therapy
US7381802B2 (en) * 2005-04-15 2008-06-03 Universidad Nacional Autónoma De México (UNAM) Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
EA014513B1 (ru) * 2005-08-03 2010-12-30 Иммьюноджен, Инк. Композиция иммуноконъюгата
BRPI0617500B8 (pt) 2005-10-17 2021-07-27 Spidertech A Div Of Stoecker & Associates A Subsidiary Of The Dermatology Center Llc kit de imunoensaio para a detecção de veneno de loxosceles reclusa
JP2007172129A (ja) * 2005-12-20 2007-07-05 Sony Corp 不揮発性メモリアクセス制御装置および不揮発性メモリ制御システム
US20070231320A1 (en) * 2006-04-03 2007-10-04 Cook Mark E Eggs having increased antibody titer and methods for making same
US8936791B2 (en) * 2006-10-18 2015-01-20 Biomerieux Method for in vitro diagnosis of PVL-producing Staphylococcus aureus
WO2008102208A2 (en) * 2006-10-20 2008-08-28 University Of Manitoba Inhibition of platelet aggregation
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
US8865169B2 (en) * 2007-02-20 2014-10-21 Tufts University Methods and systems for multi-antibody therapies
US8349326B2 (en) * 2007-02-20 2013-01-08 Tufts University Methods and systems for multi-antibody therapies
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
GEP20156390B (en) 2008-01-03 2015-11-10 Scripps Research Inst Antibody targeting through a modular recognition domain
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
TNSN08110A1 (en) * 2008-03-11 2009-07-14 Rekik Raouf Dr Drug delivery to the anterior and posterior segment of the eye from drops
ES2828627T3 (es) * 2008-04-25 2021-05-27 Kyowa Kirin Co Ltd Anticuerpo multivalente estable
US20100087455A1 (en) * 2008-10-06 2010-04-08 Auspex Pharmaceuticals, Inc. Substituted xanthine compounds
EP2355849B1 (de) * 2008-11-06 2018-05-02 University Of Guelph Verfahren zur verbesserung der therapeutischen wirksamkeit und des therapeutischen nutzens von antikörperfragmenten
PT2387583T (pt) * 2009-01-14 2018-12-24 Ablynx Nv Administração pulmonar de domínios de variável única de imunoglobulina e construtos dos mesmos
EP2230515B1 (de) * 2009-03-16 2014-12-17 Agilent Technologies, Inc. Passivierung von Oberflächen nach Ligandenkupplung
CA2763493A1 (en) * 2009-05-28 2010-12-02 Glaxo Group Ltd. Antigen-binding proteins
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
EP2563817B1 (de) * 2010-04-30 2021-09-22 UNM Rainforest Innovations Fluoreszente fusionspolypeptide und verwendungsverfahren dafür
MX2012012915A (es) 2010-05-07 2013-05-06 Camas Inc Adherencia de inmunogeno y metodo para formar y utilizar el mismo.
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
IT1402503B1 (it) * 2010-07-22 2013-09-13 Satanassi Antidoto per morso di serpenti velenosi
WO2012059928A2 (en) * 2010-11-02 2012-05-10 Josef Turner Antivenom
CA2837169C (en) 2011-05-24 2021-11-09 Zyngenia, Inc. Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
CA2839986A1 (en) * 2011-06-20 2012-12-27 St. Louis University Targeting the neuromuscular junction for treatment
WO2013009843A1 (en) 2011-07-11 2013-01-17 Camas Incorporated Compositions against bacterial toxins
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
CN107429075B (zh) 2014-11-17 2022-11-01 卡内基梅隆大学 可激活的双组份光敏剂
MA40998A (fr) 2014-11-21 2017-09-26 Ophirex Inc Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés
US11208841B2 (en) * 2017-07-14 2021-12-28 Hunter Douglas Inc. Slats with an improved route hole configuration for use within a covering and related manufacturing methods
US10286048B2 (en) * 2017-07-28 2019-05-14 James G. McCabe Polyvalent venom vaccines
US11446367B2 (en) * 2017-07-28 2022-09-20 Zootoxins, Llc Immunization with polyvalent venom vaccines
CN111620947B (zh) * 2020-06-11 2022-05-10 海南热带海洋学院 一种二价抗海蛇毒血清的制备方法
CN113214391B (zh) * 2020-12-30 2022-07-01 中国人民解放军海军军医大学 抗水母毒素纳米抗体koto54、制备方法及用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL286954A (de) * 1962-01-03
US3616229A (en) * 1968-09-27 1971-10-26 Monsanto Co Polymer-enzyme products comprising plurality of enzymes covalently bound to polymer
GB1392181A (en) * 1971-04-16 1975-04-30 Rech Et Dapplications Soc Gen Fixation of nitrogenous materials
US4165370A (en) * 1976-05-21 1979-08-21 Coval M L Injectable gamma globulin
CH626917A5 (de) * 1976-08-17 1981-12-15 Pentapharm Ag
US4550019A (en) * 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
US4357272A (en) * 1978-03-22 1982-11-02 The South African Inventions Development Corporation Recovering purified antibodies from egg yolk
DE2951412A1 (de) * 1979-12-20 1981-07-16 South African Inventions Development Corp., Pretoria, Transvaal Verfahren zur herstellung immunologisch reaktiver praeparate
US4419132A (en) * 1982-01-06 1983-12-06 American Newspaper Publishers Association Printing ink
US4748018A (en) * 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
GB8321009D0 (en) * 1983-08-04 1983-09-07 New R R C Immunological compositions
US4849352A (en) * 1984-10-09 1989-07-18 Sullivan John B Antibody purification process
US4806346A (en) * 1986-12-16 1989-02-21 American Home Products Corporation Method for isolation of antigen specific immunoglobulin
US5196193A (en) * 1989-10-31 1993-03-23 Ophidian Pharmaceuticals, Inc. Antivenoms and methods for making antivenoms

Also Published As

Publication number Publication date
US5904922A (en) 1999-05-18
AU638786B2 (en) 1993-07-08
EP0498854B1 (de) 1998-08-26
US5443976A (en) 1995-08-22
US5340923A (en) 1994-08-23
EP0498854A1 (de) 1992-08-19
ATE170079T1 (de) 1998-09-15
US5196193A (en) 1993-03-23
WO1991006306A1 (en) 1991-05-16
AU6895191A (en) 1991-05-31
EP0498854A4 (en) 1993-03-03

Similar Documents

Publication Publication Date Title
ATE170079T1 (de) Gegengifte und verfahren zu deren herstellung
DE68919466D1 (de) Verfahren zur Herstellung von schraubenförmigen, glasfaserverstärkten Befestigungselementen.
DE3780384D1 (de) Verfahren und system fuer biologische behandlung mit periodischer belueftung.
DE68923419D1 (de) Methode zur Züchtung von Bakterien.
DE3863170D1 (de) Mesophasenpech zur herstellung von kohlenstoffkoerpern und verfahren zur herstellung derselben.
DE69126762D1 (de) Biologisches Verfahren zur Herstellung von Alpha-Hydroxyamid und Alpha-Hydroxysäure
DE68913466T2 (de) Sputtertarget und Verfahren zu seiner Herstellung.
NZ223867A (en) Platelet-derived growth factor b chain (pdgf b), monoclonal antibodies to it, purification of it using the antibodies, production using genetic engineering and pharmaceuticals
DE3680632D1 (de) Verfahren zur herstellung von kohlenstoffasern und diese kohlenstoffasern.
DE3885151T3 (de) Methode zur Herstellung von Methacrylatestern.
DE68917324T2 (de) Methode zur Immobilisierung von physiologisch aktiven Substanzen.
DE69026024T2 (de) Künstlicher Träger zur Immobilisierung von biologischen Proteinen und Verfahren zu seiner Herstellung
DE68926025D1 (de) Methode zur Herstellung von alpha-Amylase hemmenden Substanzen aus Weizen
DE69002459D1 (de) Immobilisierte lipaseherstellung und deren verwendung zur herstellung von estern.
DE69419639D1 (de) Verfahren zur Herstellung von Fructose-2,6-diphosphat und Reinigungsverfahren hierfür
DE68917642D1 (de) Verfahren zur kontinuierlichen Züchtung von haftenden tierischen Zellen.
PT592685E (pt) Plantas resistentes a dois ou mais virus e sua preparacao
DE68928634T2 (de) Verfahren zur Herstellung von aktivierten Killer-Monozyten und Verfahren zur Überprüfung ihrer tumoriziden Aktivität
DE69014042D1 (de) Verfahren zur Herstellung von menschlichem Osteocalcin.
FR2619671B1 (fr) Procede de multiplication et de culture de plantes de la famille des bromeliacees, et plantes ainsi obtenues
DE3889441T2 (de) Katalytisches Verfahren zur Herstellung von optisch aktivem Threonin.
DE69302758T2 (de) Verfahren zur Behandlung von mit Kohlenwasserstoffen verunreinigtem Boden
DE3883276T2 (de) Verfahren zur Herstellung von fluorsubstituierten alicyclischen Diolen.
DE3887376D1 (de) 2-Methyl-4-amino-5-aminomethylpyrimidinkarbonat, Verfahren zu dessen Herstellung und diese brauchende Methode zur Reinigung von 2-Methyl-4-amino-5-aminomethylpyrimidin.
DE3886121D1 (de) Verfahren zur Herstellung optischer Fasern und dadurch hergestellte Produkte.

Legal Events

Date Code Title Description
8332 No legal effect for de